Brief: Sellas Announces Positive Data From Preclinical Studies Indicating Asxl1 Mutations As Predictor Of Response To SLS009 In Solid Cancers

Sellas Life Sciences

27/11/2024 13:47

Nov 27 (Reuters) - Sellas Life Sciences Group Inc
 SLS.O :
    * SELLAS ANNOUNCES POSITIVE DATA FROM PRECLINICAL STUDIES
INDICATING ASXL1 MUTATIONS AS PREDICTOR OF RESPONSE TO SLS009 IN
SOLID CANCERS
    * SELLAS LIFE SCIENCES GROUP INC: PRESELECTION METHOD FOR
CANCERS
RESPONDING TO SLS009
    * SELLAS LIFE SCIENCES GROUP INC -HIGH EFFICACY OF SLS009
OBSERVED
IN 67% OF ASXL1 MUTATED SOLID CANCERS VERSUS 0% IN NON-ASXL1
MUTATED CANCERS
    * SELLAS:  ASXL1 MUTATIONS PREDICTABLY IDENTIFIED IN
COLORECTAL
CANCER AND NON-SMALL CELL LUNG CANCER IN ADDITION TO HEMATOLOGIC
MALIGNANCIES

Source text:  ID:nGNX2g0W3x 
Further company coverage:  SLS.O 

 ((Reuters.Briefs@thomsonreuters.com;))